Oncotarget Reports on Amazing Findings

Oncotarget is a peer-reviewed journal that is distributed around the globe. Oncotarget focuses on examining the pathological effects that both cancer and cancer treatment has on the patient. In general, they look at the impact that cancer management programs have on the patient’s perspective of life and their overall satisfaction. Oncotarget is dedicated to discussing the newest treatment options that increase hope for the patient undergoing care for their cancer. Visit Soundcloud to listen an audio podcast of Oncotarget.

Recently, Oncotarget was able to report on some hopeful findings concerning treatment for papillary thyroid carcinoma. The cancer papillary thyroid carcinoma is widely known as one of the most disheartening cancers one can develop. This is due to its reputation of resisting the most common drug used in treating the cancer, vemurafenib. The reason the cancer becomes resistant to vemurafenib is that vemurafenib seeks to repair the mutated BRAF gene that causes papillary thyroid carcinoma. The body then develops in immunity to the drug so that in no longer works.

Many patients suffering from papillary thyroid carcinoma have had their cancer go into remission only to find out that it has returned incurable due to its drug resistance.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

Dr. Carmelo Nucero recently interviewed with Oncotarget to report why papillary thyroid carcinoma may now be treated with vemurafenib and another drug called palbociclib.

Dr. Carmelo Nucero was seeking to find a way to stop the body from attacking vemurafenib. After years of research and thousands of dollars, he was able to find for the first time a combination between vemurafenib and palbociclib which allowed for therapeutic strategy to treat papillary thyroid carcinoma.

The drug palbociclib is already FDA approved and has been used in breast cancer patients for years. When vemurafenib is mixed with palbociclib, the body will spend all of its time attacking palbociclib which will allow vemurafenib to continue healing the BRAF gene.

Dr. Carmelo Nucero is hopeful that since both drugs have Artie been approved by the FDA that they will soon greenlight the ability for oncologists to use this combination to treat papillary thyroid carcinoma. Download output styles at Endnote.com

To stay up-to-date subscribe to Oncotarget’s podcast now on iTunes.

Cancer expert and Chief Executive Officer-Dr. Clay Siegall

Dr. Clay Siegall is an expert in the medical field; he is also the founder and the Chief Executive Officer of Seattle Genetics which is a pharmaceutical firm which since it was created it has been concentering on the development of drugs used in diseases which are considered to be lack humanity enhancement for an extended period. Together with his partner, Dr. Clay co-founded Seattle Genetics in 1998; Clay has been at the forefront of leading the biotech organization and has helped in the success as well as the expansion of the group. Through Dr. Siegall’s experience, the firm developed their first FDA approved antibody drug conjugate. Their first drug has evolved and now has several other drugs, and more than 20 drugs are in the channel of development.

Dr. Clay Siegall went through High School, and after his graduation, he pursued his studies at the University of Maryland where he graduated with a Bachelors of Science in Zoology, and alter he attained his Ph.D.in genetics from George Washington University. Seattle has also had partnership with other pharmaceutical firms including; Genentech, Pfizer, as well as Bayer among others. Through Clay’s leadership and insight, the pharmaceutical company has grown from a small start-up to become a giant in the pharmaceutical as well as the medical industry.

Dr. Clay Siegall is the Co-founder and the Chief Executive Officer of Settle Genetics which is a leader in the manufacturing and development of drugs. Before co-founding Seattle, Clay served at Bristol- Meyer Squibb Pharmaceutical Research Institute, National Institute of Health, as well as National Cancer Institute. He is a leader who has shown positive leadership character as well as an incredible leadership that is why he has served on several Board of governors include; Ultragenyx Pharmaceuticals as the Board of Director, Washington Roundtable, and Alder BioPharmaceuticals. Having an experience which runs for many years; the doctor who has a passion for cancer patients, as well as the treatment, has been recognized on various occasions. Some of the awards which he has received include; the Year of Computer at the University of Maryland among many others. He is not only a medical doctor, but he is also an author.